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Abstract
Background: Microarray analysis still is a powerful tool to identify new components of the
transcriptosome. It helps to increase the knowledge of targets triggered by stress conditions such
as hypoxia and nitric oxide. However, analysis of transcriptional regulatory events remain elusive
due to the contribution of altered mRNA stability to gene expression patterns as well as changes
in the half-life of mRNAs, which influence mRNA expression levels and their turn over rates. To
circumvent these problems, we have focused on the analysis of newly transcribed (nascent) mRNAs
by nuclear run on (NRO), followed by microarray analysis.
Results: We identified 196 genes that were significantly regulated by hypoxia, 85 genes affected by
nitric oxide and 292 genes induced by the cotreatment of macrophages with both NO and hypoxia.
Fourteen genes (Bnip3, Ddit4, Vegfa, Trib3, Atf3, Cdkn1a, Scd1, D4Ertd765e, Sesn2, Son, Nnt, Lst1,
Hps6 and Fxyd5) were common to all treatments but with different levels of expression in each
group. We observed that 162 transcripts were regulated only when cells were co-treated with
hypoxia and NO but not with either treatment alone, pointing to the importance of a crosstalk
between hypoxia and NO. In addition, both array and proteomics data supported a consistent
repression of hypoxia-regulated targets by NO.
Conclusion: By eliminating the interference of steady state mRNA in gene expression profiling,
we obtained a smaller number of significantly regulated transcripts in our study compared to
published microarray data and identified previously unknown hypoxia-induced targets. Gene
analysis profiling corroborated the interplay between NO- and hypoxia-induced signaling.
Background
Hypoxia causes cellular stress. In order to survive cells turn
on adaptive mechanisms to improve oxygen transport
and to ensure sufficient cellular ATP supply [1]. Central to
this adaptation is the transcription factor hypoxia-induci-
ble factor-1 (HIF-1), which stimulates genes involved in
angiogenesis, erythropoiesis and glycolysis [2-4]. HIF-1
consists of an O2-regulated α-subunit (HIF-1α) and a con-
stitutively expressed β-subunit (HIF-1β). Under normoxic
conditions HIF-1α is continuously degraded by a family
of prolyl hydroxylase domain-containing enzymes
(PHD1, PHD2, PHD3), which hydroxylate two proline
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residues (Pro-402 and Pro-564) in the oxygen-dependent
degradation domain of HIF-1α [5,6]. This allows its recog-
nition by the von Hippel-Lindau protein E3 ubiquitin
ligase complex and proteasomal degradation [7,8]. Con-
versely, under hypoxia hydroxylation of HIF-1α is
impaired, proteasomal degradation is offset thus, provok-
ing its accumulation. HIF-1α is hydroxylated in an oxy-
gen-dependent manner pointing to PHDs as the cellular
oxygen sensors [9-11]. In addition to the regulation of
HIF-1α protein stability, the transcriptional activity of
HIF-1 is regulated by hydroxylation of Asn-803 in the C-
terminal trans-activating domain of HIF-1α. An asparagyl
hydroxylase known as factor inhibiting HIF (FIH) [1] cat-
alyzes this modification and interferes with the transcrip-
tional activity of HIF-1α by blocking cofactor binding, e.g.
p300/CREB [12].
Besides hypoxia, nitric oxide (NO) and/or NO-derived
species regulate HIF-1α abundance and activity. Under
normoxic conditions, NO donors induce HIF-1α stabili-
zation and transcriptional activation of HIF-1 target genes
[13-15]. Mechanistically, NO-dependent inhibition of
PHD activity accounts for HIF-1α protein stabilization
[16], although increased synthesis mediated by phos-
phatidylinositol 3-kinase or mitogen-activated protein
kinase has been noticed [14]. Paradoxically, under
hypoxic conditions, NO appears to destabilize rather than
to stabilize HIF-1α. Nitric oxide donors (DETA-NO,
GSNO) decrease hypoxia-elicited HIF-1α stabilization
and HIF-1 transcriptional activation [17-19]. It is sug-
gested that mitochondria play a role in NO-mediated reg-
ulation of HIF-1α under hypoxia [20-23]. Hagen et al.
proposed that inhibition of cytochrome c oxidase by NO
during hypoxia reduced mitochondrial oxygen consump-
tion, leaving more oxygen available for PHDs to regain
activity thus, allowing HIF-1α degradation [21]. Further-
more, NO-derived species and/or reactive oxygen species
have been suggested to destabilize HIF-1α by their ability
to reactivate PHDs [24,25]. Recently, calcium induced
activation of calpain were also implicated in the degrada-
tion of HIF-1α by NO under hypoxia, adding a layer of
complexity to HIF-1 regulation [15]. Since hypoxia and
NO modulate HIF-1α in different microenvironments, we
were prompted to investigate whether the modulation of
HIF-1α by hypoxia or NO would generate identical or
restricted gene profiles. Using pairwise comparison of the
gene profile data generated by cells treated with hypoxia
and/or NO, we were able to study the influence of NO on
the gene expression profile of hypoxia-induced genes, as
well as that of hypoxia on NO-induced genes. Herein we
have used a combined NRO and microarray approach to
study the crosstalk between hypoxia/NO on the genetic
profile of hypoxia- or NO-regulated genes in RAW 264.7
macrophages.
Results and Discussion
Transcripts generated by hypoxia and/or DETA-NO in 
macrophages
The intention of this study was to identify hypoxia- or
nitric oxide-regulated genes by a systematic analysis of de
novo (nascent) transcription and to question whether reg-
ulation of HIF1α by hypoxia or nitric oxide would gener-
ate overlapping gene profiles. We chose to analyze newly
synthesized mRNA obtained by NRO. This allowed detec-
tion of bona fide transcriptionally regulated genes, thus
reducing the interference of steady-state mRNA turnover
on the pool of expressed mRNA common to conventional
microarray analysis. Therefore, RAW 264.7 cells were
exposed to hypoxia (1% O2), DETA-NO (0.5 mM), or a
combination of hypoxia and NO for 6 h. Transcriptional
changes were systematically assessed using Affymetrix
microarray analysis, which allowed following 32000 tran-
scripts. [26]. Most gene transcripts (> 99% of genes on the
array) remained unchanged by either hypoxia or NO, as
well as in the combination of both. Only 196 genes were
regulated by hypoxia with the majority being upregulated
[see Additional file 1]. The greater number of the tran-
scripts regulated by hypoxia is linked to energy consump-
tion through glycolysis. Nitric oxide regulated a set of 85
genes shown in supplementary table 2 [see Additional file
2], while treatment of cells with both hypoxia and NO
regulated 292 transcripts [see Additional file 3]. Figure 1
gives an overview of all groups with their number of regu-
Venn diagram of grouped genes Figure 1
Venn diagram of grouped genes. Analysis of gene 
expression in RAW cells subjected to hypoxia (1% O2) and/
or 0.5 mM DETA-NO for 6 h. After removing double and 
unknown transcripts data represent total number of genes 
regulated by each treatment (in parentheses) as well as over-
lapping genes shared by treatments. A complete list of genes 
for each treatment is provided in the supplementary tables 1-
3. Detailed information of genes from the intersections is 
given in table 1-5.BMC Genomics 2009, 10:408 http://www.biomedcentral.com/1471-2164/10/408
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lated genes. Comparing gene profiles following treat-
ments with hypoxia and/or NO, we observed that only 14
genes (Bnip3, Ddit4, Vegfa, Trib3, Atf3, Cdkn1a, Scd1,
D4Ertd765e, Sesn2, Son, Nnt, Lst1, Hps6, and Fxyd5)
were common to all treatments. It is not surprising that
many of these genes have roles in cell death, DNA damage
and apoptosis since under stress conditions cells try to
avoid cell demise. Most of these genes had been previ-
ously described as hypoxia or NO regulated [27-29],
underscoring the validity of this approach. Interestingly, 9
of the 14 common genes (Bnip3, Ddit4, Vegfa, Trib3,
Atf3, Cdkn1a, Scd1, D4Ertd765e, Sesn2) were upregu-
lated by hypoxia and/or NO, whereas 5 (Son, Nnt, Lst1,
Hps6, and Fxyd5) were downregulated (Table 1). Most
genes upregulated by hypoxia or NO were more strongly
regulated under hypoxia, with the exception of Scd1 and
Sesn2, whose levels were slightly higher with NO. For the
commonly downregulated genes 4 out of the 5 identified
ones were regulated to the same extent by hypoxia or NO.
Interestingly, only one gene being downregulated (Fxyd5
a glycoprotein containing a Na+- K+-ATPase domain)
revealed different levels of inhibition between hypoxia
and NO, albeit being the strongest suppressed gene in the
list. Hypoxia and NO downregulated Fxyd5 4.2-folds and
18.27-folds compared to controls. Contrary to the finding
in this study, Fxyd5 has been shown to be upregulated in
the mouse carotid body in response to 10% hypoxia [30],
suggesting a different regulation pattern for this protein at
different oxygen pressures. Fxyd5 affects the ion transport
system of the blood brain barrier and modulates Na+
absorption during cystic fibrosis [31]. The notion that NO
decreased chloride adsorption by reducing Na+-K+-2Cl-
cotransporter activity and inhibits transepithelial ion
movement in cystic fibrosis [32] corroborates our finding
on repression of Fxyd5. Fxyd5 interacts with the Na+-K+-
ATPase and modulates its properties after NO-treatment
[33].
In table 2 we listed a total of 18 genes common to macro-
phages treated with hypoxia or NO alone. The 18 tran-
scripts consist of the 14 transcripts found in all treatments
(Table 1) plus additional 4 transcripts (Frat2, CD52, Mafb
and Ccl3). Eleven of the 18 genes were upregulated and 7
were downregulated by NO, while 10 genes were upregu-
lated and 8 were downregulated by hypoxia. Interestingly
in this category we identified Ccl3 (C-C motif) ligand 3,
Table 1: 14 Genes common to all treatments; hypoxia, NO and hypoxia plus NO for 6 h.
Symbol Gene name Ac NO Hyp Hyp + NO
Bnip3 BCL2/adenovirus E1B 19 kDa-interacting protein 1, NIP3 NM_009760.2 2.53 33.40 20.06
Ddit4 DNA-damage-inducible transcript 4 NM_029083.1 5.19 19.68 35.21
Vegfa vascular endothelial growth factor A NM_009505.2 2.06 9.08 6.55
Trib3 tribbles homolog 3 (Drosophila) NM_144554.1 5.85 8.05 27.11
Atf3 activating transcription factor 3 NM_007498.2 2.37 7.27 7.26
Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) NM_007669.2 2.07 2.89 4.25
Scd1 stearoyl-Coenzyme A desaturase 1 NM_009127.2 4.18 2.54 3.55
D4Ertd765e DNA segment, Chr 4, ERATO Doi 765, expressed NM_026728.1 2.91 2.52 2.30
Sesn2 sestrin 2 NM_144907.1 3.47 2.32 5.23
Son Son cell proliferation protein NM_178880.3 -2.06 -2.16 -2.23
Nnt nicotinamide nucleotide transhydrogenase AK087064.1 -2.04 -2.39 -2.41
Lst1 leukocyte specific transcript 1 NM_010734.1 -2.26 -2.62 -2.55
Hps6 Hermansky-Pudlak syndrome 6 NM_176785.1 -4.86 -3.74 -4.21
Fxyd5 FXYD domain-containing ion transport regulator 5 BC031112.1 -18.27 -4.20 -9.71
This list was obtained by comparing profiles of genes detected by the three treatments, excluding duplicate transcripts, unknown transcripts and 
transcripts not detected in one or two of the treatments. NO = nitric oxide (0.5 mM DETA-NO); Hyp = hypoxic treatment (1% O2).BMC Genomics 2009, 10:408 http://www.biomedcentral.com/1471-2164/10/408
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known as macrophage inflammatory protein 1 alpha
(MIP1α), to be downregulated by hypoxia but upregu-
lated by NO. Recent studies have shown that hypoxia pref-
erentially regulates the accumulation of mononuclear
phagocytes in hypoxic/ischemic areas [34,35]. Our data
show that NO alone upregulated Ccl3 twofold compared
to untreated cells, whereas hypoxia downregulated Ccl3
twofold. This finding correlates well with the report that
hypoxia downregulates several members of the C-C ligand
chemokine family including Ccl3 (MIP1α), MIP1β or
Ccl2 (MCP-1) [36] or Ccl15, Ccl18 Ccl19 and Ccl23 [34].
Considering that chemokine signaling regulates mono-
cyte/macrophage recruitment to inflammatory sites
downregulation of these mediators by hypoxia may be
necessary to prevent cell death and to limit the influx of
pro-inflammatory cytokine producing cells. In contrast,
NO with its pro- and anti-inflammatory properties upreg-
ulated Ccl3. Nitric oxide was shown to be coregulated
with the chemokine MCP-1 in Kupffer cells treated with
LPS [37] but a causative role for NO in MCP-1 regulation
could not be established. However, there is evidence that
NO is required for LPS-induced MCP-1 or MRP1 expres-
sion [38]. It is important that Ccl3, regulated either by
hypoxia or NO alone, showed no expression regulation
when cells were subjected to both treatments. This obser-
vation indicates a complex interplay between hypoxia and
NO, with signal elimination under hypoxia/NO.
Considering that HIF-1 regulates a number of genes under
hypoxia [39] or in response to NO, we were interested to
Table 2: 18 Genes common to treatments with hypoxia or nitric oxide.
Symbol Gene Name Ac NO Hyp
Bnip3 BCL2/adenovirus E1B 19 kDa-interacting protein 1, NIP3 NM_009760.2 2.53 33.40
Ddit4 DNA-damage-inducible transcript 4 NM_029083.1 5.19 19.68
Vegfa vascular endothelial growth factor A NM_009505.2 2.06 9.08
Trib3 tribbles homolog 3 (Drosophila) NM_144554.1 5.85 8.05
Atf3 activating transcription factor 3 NM_007498.2 2.37 7.27
Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) NM_007669.2 2.07 2.89
Scd1 stearoyl-Coenzyme A desaturase 1 NM_009127.2 4.18 2.54
D4Ertd765e DNA segment, Chr 4, ERATO Doi 765, expressed NM_026728.1 2.91 2.52
Frat2 frequently rearranged in advanced T-cell lymphomas 2 NM_177603.1 2.15 2.49
Sesn2 sestrin 2 NM_144907.1 3.47 2.32
Cd52 CD52 antigen NM_013706.1 -2.02 -2.15
Son Son cell proliferation protein NM_178880.3 -2.06 -2.16
Mafb v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) NM_010658.2 -2.49 -2.32
Nnt nicotinamide nucleotide transhydrogenase AK087064.1 -2.04 -2.39
Ccl3 chemokine (C-C motif) ligand 3 X12531.1 2.22 -2.42
Lst1 leukocyte specific transcript 1 NM_010734.1 -2.26 -2.62
Hps6 Hermansky-Pudlak syndrome 6 NM_176785.1 -4.86 -3.74
Fxyd5 FXYD domain-containing ion transport regulator 5 BC031112.1 -18.27 -4.20
Gene transcripts regulated by hypoxia (1% O2) or NO (0.5 mM DETA-NO) were analyzed to identify overlapping genes in these set of data. Hyp = 
hypoxia treatment; NO = nitric oxide treatment.BMC Genomics 2009, 10:408 http://www.biomedcentral.com/1471-2164/10/408
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examine opposing regulation patterns. Therefore, we ana-
lyzed to what extent hypoxia affects the gene profile gen-
erated by NO. We compared profiles of cells treated with
NO to cells treated with NO plus hypoxia (Table 3). We
identified 40 genes in response to NO or hypoxia plus
NO. The patterns of gene profiles were similar for both
treatments, though significant differences exist in the
expression levels of some transcripts in response to NO or
hypoxia/NO. Thirty of the transcripts (75%) were upregu-
lated and only 10 (25%) were downregulated by both
treatments. However, we noticed gene specific regulation
when both data were compared. The majority of the
upregulated genes (17 genes; 56.7%) revealed no changes
in their expression when hypoxia was added to NO while
12 transcripts (40%) were increased 2- to 6-fold, com-
pared to treatments with NO alone. This suggests an addi-
tive effect cause by hypoxia on the expression of these
transcripts. Amongst the commonly upregulated genes
only one transcript (Scd1) was moderately upregulated
when cells were cotreated with hypoxia plus NO com-
pared to NO alone. For most of the transcripts downregu-
lated by NO, 9 genes (90%) did not show changes in their
expression levels in the presence of hypoxia compared to
their expression with NO alone. Interestingly Fxyd5,
which was the most prominent downregulated transcript
by NO (18-folds) was significantly relieved of this effect
when subjected to hypoxia plus NO.
In another set of data analysis we determined the effect of
NO on the gene profiles of hypoxia-generated transcripts.
A comparison of gene profiles generated by hypoxia was
performed against the profile generated by cells treated
with hypoxia plus NO [Additional file 4]. A total of 100
transcripts were obtained in this category, with 81 genes
being upregulated, while 20 were downregulated by both
conditions (hypoxia vs. or hypoxia plus NO). Fifty-five
transcripts upregulated under both conditions did not
show significant changes in expression profiles when NO
was added compared to hypoxia alone, whereas 26 genes
in this category (32.1%) were influenced by NO. Interest-
ingly, amongst the 26 genes that showed changes in gene
expression due to the presence of NO, the majority of 17
genes (65.4%) showed a lower level of expression when
cells were cotreated with hypoxia and NO compared to
hypoxia alone. This suggests that NO attenuated the
induction of hypoxia-induced transcripts. One plausible
explanation for this observation could be attributed to the
ability of NO to destabilize HIF-1α under hypoxic condi-
tion. Further studies involving HIF-1α deficient cells are
necessary to support the role of HIF-1α in this process. On
the other hand, NO was able to augment the expression of
a few transcripts (9 genes, 34.6%) upregulated by hypoxia
alone. The heterogeneous influence of NO on hypoxia-
regulated gene profiles is in agreement with its ability to
participate in direct and indirect signaling and to induce
overlapping signaling pathways with hypoxia. NO acti-
vates soluble guanylyl cyclase to generate cGMP and in
turn to activate cGMP-dependent protein kinases [40].
NO also reacts with superoxide (O2
-) to generate perox-
ynitrite (ONOO-), potentially causing tissue damage and
nucleic acid modifications [40,41]. There is evidence that
large amounts of NO and ROS, produced during inflam-
mation shift the NO chemistry towards indirect effects
such as nitrosation, nitration and oxidation [42].
Finally, we compared the array data from all treatments to
identify transcripts that were only seen in cells cotreated
with hypoxia and NO but neither with hypoxia or NO
alone. One-hundred and sixty-two unique transcripts
were identified in this category, suggesting that the cross-
talk between hypoxia and NO might be responsible for
their regulation. The majority of the transcripts (122
genes, 75.9%) were upregulated, while the other 40 tran-
scripts (24.1%) were downregulated [Additional file 5]. A
few of the genes identified here had been reported by
other investigators to be regulated by NO (e.g., SparC,) or
hypoxia (e.g. Clk, Myd116, Ceacam1) but not by the com-
bination of both. The majority of the unique transcripts
identified in this study are unknown to be hypoxia or NO-
dependent. This finding suggests alternative pathways for
the regulation of these unique transcripts, which may
involve multiple scenarios of cross-talks between hypoxia
and NO operating in inflammation or cancer. Taken
together, from our analysis and gene expression profiles
generated in many array studies with different cell types,
one can conclude that there is a core of genes consistently
modulated by hypoxia or NO, while a large number of
genes exhibited cell-type-specific changes.
Verification of micro array data by qRT-PCR analysis
Despite the fact that our microarray data can be correlated
to previous array studies with similar regulation patterns
for several gene transcripts, we performed an independent
validation of our data by RT-PCR after the isolation of
whole cell RNA either from RAW 264.7 or primary mouse
macrophages. Nine genes (ATF3, Ddit4, Sesn2, Vegf1,
Trib3, Cdkn1a, Bnip3, Frat2 and Scd1) that were either
up- or downregulated in our as well as other arrays, were
chosen. Result obtained by RT-PCR (Table 4) confirmed
the regulation pattern of the selected genes obtained by
microarray analysis. However, there were gene specific
variations in the expression levels for some of the tran-
scripts. Changes in gene expression levels obtained with
RT-PCR tend to be slightly lower compared to microarray
data for most of the genes examined. Similar observations
have been reported by other studies [43] and were attrib-
uted to different factors, including the sensitivity of the
different methods, cross-interference between transcripts
because of the large size of transcripts examined together
(multiplexing) and the quality of mRNA [44].BMC Genomics 2009, 10:408 http://www.biomedcentral.com/1471-2164/10/408
Page 6 of 13
(page number not for citation purposes)
Table 3: Impact of hypoxia on genes regulated by NO.
Symbol Gene Name Ac NO Hyp + NO
Ddit4 DNA-damage-inducible transcript 4 NM_029083.1 5.19 35.21
Trib3 tribbles homolog 3 (Drosophila) NM_144554.1 5.85 27.11
Bnip3 BCL2/adenovirus E1B 19 kDa-interacting protein 1, NIP3 NM_009760.2 2.53 20.06
Phlda3 pleckstrin homology-like domain, family A, member 3 NM_013750.1 3.88 9.41
Nqo1 NAD(P)H dehydrogenase, quinone 1 U12961.1 2.99 8.32
Atf3 activating transcription factor 3 NM_007498.2 2.37 7.26
Vegfa vascular endothelial growth factor A NM_009505.2 2.06 6.55
Sesn2 sestrin 2 NM_144907.1 3.47 5.23
Adh7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide NM_009626.2 2.71 5.06
Gpt2 glutamic pyruvate transaminase (alanine aminotransferase) 2 NM_173866.1 2.49 5.02
Slc7a11 solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 NM_011990.1 2.68 4.74
Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) NM_007669.2 2.07 4.25
Scd1 stearoyl-Coenzyme A desaturase 1 NM_009127.2 4.18 3.55
Sfrs1 splicing factor, arginine/serine-rich 1 (ASF/SF2) NM_173374.2 2.82 3.42
Slc19a2 solute carrier family 19 (thiamine transporter), member 2 NM_054087.1 2.32 3.08
Atp6ap2 ATPase, H+ transporting, lysosomal accessory protein 2 NM_027439.2 2.31 2.62
Txndc1 thioredoxin domain containing 1 NM_028339.1 2.03 2.58
Adam10 a disintegrin and metalloprotease domain 10 NM_007399.1 2.07 2.55
Lss lanosterol synthase AK012813.1 2.12 2.48
Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 NM_021451.1 2.27 2.46
Eif4g2 eukaryotic translation initiation factor 4, gamma 2 NM_013507.2 2.16 2.45
Sgpp1 sphingosine-1-phosphate phosphatase 1 NM_030750.2 3.00 2.42
Rbl2 retinoblastoma-like 2 NM_011250.2 2.01 2.33
D4Ertd765e DNA segment, Chr 4, ERATO Doi 765, expressed NM_026728.1 2.91 2.30
Vcl vinculin NM_009502.3 2.02 2.22
Pabpc1 poly A binding protein, cytoplasmic 1 NM_008774.2 2.11 2.19
Golph3 golgi phosphoprotein 3 NM_025673.2 2.18 2.15
Rrm1 ribonucleotide reductase M1 NM_009103.2 2.97 2.11BMC Genomics 2009, 10:408 http://www.biomedcentral.com/1471-2164/10/408
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Nsmaf neutral sphingomyelinase (N-SMase) activation associated factor NM_010945.1 2.43 2.05
Dirc2 disrupted in renal carcinoma 2 (human) NM_153550.2 2.23 2.03
Crip1 cysteine-rich protein 1 (intestinal) NM_007763.1 -2.13 -2.09
Trerf1 transcriptional regulating factor 1 NM_172622.1 -2.14 -2.12
Rps19 ribosomal protein S19 NM_023133.1 -2.04 -2.18
Son Son cell proliferation protein NM_178880.3 -2.06 -2.23
Idb1 inhibitor of DNA binding 1 NM_010495.1 -2.45 -2.36
Nnt nicotinamide nucleotide transhydrogenase AK087064.1 -2.04 -2.41
Dhrs6 dehydrogenase/reductase (SDR family) member 6 NM_027208.1 -2.60 -2.42
Lst1 leukocyte specific transcript 1 NM_010734.1 -2.26 -2.55
Hps6 Hermansky-Pudlak syndrome 6 NM_176785.1 -4.86 -4.21
Fxyd5 FXYD domain-containing ion transport regulator 5 BC031112.1 -18.27 -9.71
This list of 40 genes was obtained by comparing the NO (0.5 mM DETA-NO)-generated gene profile to that generated by hypoxia (1% O2) plus 
NO. Hyp = hypoxia treatment; NO = nitric oxide treatment.
Table 3: Impact of hypoxia on genes regulated by NO. (Continued)
Table 4: RT-PCR analysis of genes selected form the microarray profile.
RAW Primary Macrophages
Symbol Ac Hyp NO Hyp NO
Vegf1 NM_009505.2 5.7 ± 0.27 2.0 ± 0.14 5.5 ± 0.84 3.0 ± 0.46
Ddit4 NM_029083.1 16.6 ± 0.58 3.6 ± 0.53 2.4 ± 0.37 1.4 ± 0.30
Sesn2 NM_144907.1 2.0 ± 0.47 4.2 ± 0.33 2.5 ± 0.64 3.6 ± 0.70
Bnip3 NM_009760.2 24.1 ± 0.42 2.3 ± 0.40 3.6 ± 0.57 2.2 ± 0.56
Trib3 NM_144554.1 3.0 ± 0.51 3.4 ± 0.61 1.5 ± 0.32 1.7 ± 0.35
Atf3 NM_007498.2 4.6 ± 0.54 1.3 ± 0.27 0.9 ± 0.35 0.9 ± 0.31
Frat2 NM_177603.1 2.0 ± 0.45 1.3 ± 0.43 2.1 ± 0.63 1.6 ± 0.51
Cdkn1a NM_007669.2 3.6 ± 0.61 2.3 ± 0.28 5.3 ± 1.33 4.2 ± 1.30
Scd1 NM_009127.2 1.3 ± 0.20 0.9 ± 0.60 1.0 ± 0.30 1.4 ± 0.54
RAW cells were subjected to hypoxia (1% O2) or NO (0.5 mM DETA-NO) for 6 h and primary macrophages for 12 h. Whole cell mRNA was 
isolated and analyzed by qRT-PCR. Expression changes of 9 genes were evaluated in relation to the values obtained in parallel for 16S ribosomal 
protein obtained from 4 individual experiments. Hyp = hypoxic treatment; NO = nitric oxide treatment.BMC Genomics 2009, 10:408 http://www.biomedcentral.com/1471-2164/10/408
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Proteomics analysis
A number of studies addressed the question whether
changes in mRNA are reflected in corresponding changes
in protein abundance [41,45-47]. Often, poor correla-
tions have been reported between RNA transcriptions and
protein levels and in some cases, little or no correlations
were obtained [46]. Given the complexities of protein
expression and the many stages at which it may be con-
trolled, differences between RNA expression and protein
expression are perhaps to be expected. Nevertheless we
performed 2-D gel protein analysis to examine a genome
wide change in protein expression of RAW cells after
hypoxia- and NO-treatments to verify array data. Sample
aliquots were labeled with two different fluorescent dyes
(Cy3 and Cy5) and the internal control standard, actin,
was stained with Cy2. 2-D PAGE was prepared and run as
previously described [48]. Gels were scanned and data
analysis was preformed by the Bioinformatic Section of
Genedata, Basel, Switzerland. Comparing the intensity of
the fluorescence of the scanned gels containing four sam-
ples for each treatment (untreated or hypoxia treated), we
identified 19 spots that showed at least twofold higher or
lower changes in protein expression compared to controls
(Figure 2). Expression changes in 13 (all 19 except spots
1, 120,100,110,121 and 295) spots, regulated after
hypoxia, were significant as estimated by the student T-
test (< 0.05). Eight (61.5%) of the 13 significantly regu-
lated spots were upregulated, whereas 5 (38.5%) were
downregulated. Interestingly, this finding correlates with
our array studies, where hypoxia upregulated more gene
transcripts than it downregulated.
To analyze the effect of NO on hypoxia regulated spots,
we compared the expression patterns of hypoxia vs.
hypoxia plus NO data (Figure 3). Twenty-one spots
showed at least +2 or -2 folds changes in protein expres-
sion when cells were treated with hypoxia alone com-
pared to cells treated with a combination of hypoxia and
NO. Thirteen of the regulated proteins were significant by
student T-test. In this analysis, the majority, 9 spots
(69.2%) out of the 13 significant spots were downregu-
lated and only 4 spots (9, 10,105 and 125) were up regu-
lated. The higher number of downregulated spots seen
when cells were cotreated with hypoxia and NO is consist-
ent with the array data and suggest that NO predomi-
nantly attenuates gene expression when combined with
hypoxia. Furthermore, spots 2, 5, 6, 96, and 98 of figure 2,
which were significantly upregulated by hypoxia, were
downregulated when macrophages were cotreated with
hypoxia and NO (Figure 3). There was a strong correlation
between the array and the proteomics data based on regu-
latory patterns seen on gene regulation profiles as a whole
as well as on the effect of NO on hypoxia regulated gene
patterns. However, at the level of individual proteins, we
were unable to prove corresponding gene regulation pat-
terns for specific genes/proteins. Finally to identify and
annotate some of the differentially expressed spots of
interest, we conducted mass spectrometry (MS) analysis.
A total of 11 spots significantly regulated by hypoxia and/
or NO were chosen for further identification. We identi-
fied spots 2, 6, 96, 97 and 98, which were significantly
upregulated by hypoxia in this study as cofilin-1
(P45594), ferretin heavy chain (P09528, P02794), comm
domain-containing protein7 (Q8BG94), ferritin light
chain-1 protein (P15532) and peroxiredoxin (P35700),
respectively. Consistent with our studies, antioxidants
(peroxiredoxins), iron homeostatic (ferritin) and cofilin-
1 are implicated in the hypoxia signaling cascade [48-51].
Interestingly, we are reporting for the first time the identi-
fication of comm domain containing protein 7 as signifi-
cantly upregulated in cells treated with hypoxia.
Presumably all COMM_Domain containing proteins are
located in the nucleus and the COMM domain plays a role
in protein-protein interactions. Several family members
have been shown to bind and inhibit NF-κB. Other pro-
teins identified in this study include nucleoside diphos-
phate kinase B (spot 7, P15532) and 40S ribosomal
protein S5 (P97461), which were significantly downregu-
lated when macrophages were cotreated with hypoxia and
NO but not by hypoxia alone. The interplay between NO
and hypoxia has important functional implications,
expanding and enriching the possibilities for modulating
stress responses.
Conclusion
By eliminating the interference of steady state mRNA in
gene expression profiling, we obtained lower number of
Proteomics data of macrophages subjected to hypoxia for 6  hour vs. untreated cells Figure 2
Proteomics data of macrophages subjected to 
hypoxia for 6 hour vs. untreated cells. The scanned gel 
contains four samples for each treatment (untreated or 
hypoxia (1% O2) treated) and a column comparing the 
median intensities of the same spot for the four samples in 
each treatment. Spot colors indicate: upregulation (red), 
downregulation (green), no change in regulation (dark/black). 
Student t-test for significantly regulated spots (< 0.05) is indi-
cated by blue vertical bars.
Spots
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significantly regulated transcripts in our study compared
to published microarray data and identified previously
unknown hypoxia-induced targets. Gene analysis profil-
ing corroborated the interplay between NO- and hypoxia-
induced signaling.
Methods
Cell culture
RAW 264.7 cells were cultured in RPMI 1640 supple-
mented with 2 mM glutamine, 100 units/ml penicillin,
100 μg/ml streptomycin and 10% fetal calf serum. Pri-
mary peritoneal mouse macrophages were isolated by
peritoneal lavage with 15 ml PBS, supplemented with
10% fetal calf serum and cultured in RPMI 1640 with sup-
plements as described. Cells were kept at 37°C in a
humidified atmosphere with 5% CO2.
Nuclei isolation
6 × 106 RAW 264.7 cells were seeded in 10-cm dishes one
day prior to experiments. The following day, medium was
changed, cells were treated as indicated and harvested.
Nuclei were prepared in 200 μl hypotonic lysis buffer (10
mM Hepes, 0.1 mM EDTA, 2 mM MgCl2, 10 mM KCl, pro-
tease inhibitor cocktail, 1 mM DTT, 5 mM PMSF, pH 7.9)
and incubated on ice for 10 min. After centrifugation (500
× g, 30 min, 4°C), the supernatant was discarded and
nuclei were resuspended in 150 μl nuclei storage buffer
(50 mM Tris-HCl, 0.1 mM EDTA, 5 mM MgCl2, and 40%
glycerol, pH 8.3). Stalled transcriptions were allowed to
resume following exogenous addition of nuclear run-on
reaction buffer and reaction proceeded for 30 min at
30°C. Nuclear RNA was isolated, extracted and cDNA was
hybridized to a mouse genomic array chip containing
32000 genes as previously described [26].
Nuclear run-on
1 × 107 nuclei in 150 μl storage buffer were added to 150
μl nuclear run-on reaction buffer (10 mM Tris-HCl, 5 mM
MgCl2, 300 mM KCl, 1 mM ATP, 1 mM GTP, 1 mM CTP,
1 mM UTP, pH 8.0) and nuclear run-on was performed
for 30 min at 30°C. Nuclear RNA was isolated using the
peqGOLD RNAPure kit according to manufacture's
instructions (Peqlab, Erlangen, Germany).
Microarray analysis
Identification of differentially expressed genes between
normoxic and hypoxic treated NPC cells was carried out
using GeneChip_Mous Genome Arrays (Affymetrix, Santa
Clara, CA), which represented 32000 transcripts. In brief,
10 μg of total RNA was used to synthesize cDNA. The
cDNA was then used as a template to generate bioti-
nylated cRNA by in vitro transcription. The cRNA was sub-
sequently fragmented. The quality and size distribution of
total RNA, cRNA and fragmented cRNA were checked on
an Agilent 2100 Bioanalyzer (Agilent, Amstelveen, The
Netherlands), using RNA 6000 Pico assay. The frag-
mented cRNA was hybridized to the GeneChip arrays. The
arrays were then washed, stained and finally scanned with
a laser scanner. The scanned images were processed with
GeneChip_Microarray Suite 5.0 (Affymetrix). Compari-
son between expression profiles of the normoxic and
hypoxic and/or NO were performed using
GeneSpring_software version 7 (Silcongenetics, Red-
wood, California). Gene expression data were first nor-
malized by GC-RMA (robust multichip average)
preprocessor. Normalized values below 0.001 were set to
0.001. The normalized expression values were then com-
pared between normoxic and hypoxic, normoxic and
nitric oxide, as well as for normoxia and hypoxia plus
nitric oxide. Fold change differences were calculated to
identify the up- and down-regulated genes. Statistical
algorithms implemented in the Affymetrix microarray
analysis software were applied to identify genes whose
overall expression level in three independent experiments
was altered at least 2-fold up or down by hypoxia and/or
NO compared to untreated controls. To compare the gene
profiles of the different treatments and to determine the
number of transcripts regulated by each treatment, we
eliminated duplicates of transcripts represented more
than once as well as transcripts with unknown gene iden-
tification numbers.
Quantitative real time RT-PCR
RT-PCR analyses were performed for a selection of upreg-
ulated and downregulated genes to confirm their differen-
Proteomics data comparing effects of nitric oxide on hypoxia  regulated spots Figure 3
Proteomics data comparing effects of nitric oxide on 
hypoxia regulated spots. RAW cells were subjected for 6 
hours to hypoxia (1% O2) or hypoxia plus NO (0.5 mM 
DETA-NO). The scanned gel contains four samples for each 
treatment (hypoxia or hypoxia plus NO) and a column com-
paring the median intensities of the same spot for the four 
samples in each treatment. Spot colors indicate: upregulation 
(red), downregulation (green), no change in regulation (dark/
black). Student t-test for significantly regulated spots (< 0.05) 
is indicated by blue vertical bars.
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tial expressions. 2 × 106 RAW 264.7 cells and/or primary
peritoneal macrophages were seeded in 10-cm dishes one
day prior to experiments. The following day medium was
changed and cells were treated as indicated. Total RNA
was isolated using the peqGOLD RNAPure kit (Peqlab,
Erlangen, Germany). The reverse transcription was com-
pleted from 1 μg RNA with a IScript™ cDNA Synthesis RT-
PCR kit. The quantitative real time PCR was performed by
MyiQ (Bio-Rad). Reaction mixtures containing SYBR
Green were composed according to the manufacturer pro-
tocol. The cycling program was: 50°C, 2 minutes; 95°C,
15 minutes; followed by 35 cycles at 95°C, 15 seconds;
60°C, 30 seconds; 72°C, 30 seconds. Values of Atf3,
Ddit4, Vegf1, Bnip3, Sesn2, Cdkn1a and Frat2 were then
normalized to 16S ribosomal protein. The following
primer pairs were selected for quantitative real time PCR:
Vegf1 forward: 5'-CAGGCTGCTGTAACGATGAA-3', Vegf1
reverse: 5'-GCATTCACATCTG-CTGTGCT-3'; Bnip3 for-
ward: 5'-GGTTTTCCCCAAAGGAATA-3', Bnip3 reverse: 5'-
TGACCACC-CAAGGTAATGGT-3'; Atf3 forward: 5'-
CAGAGCCTGGTGTTGTGCTA-3,' Atf3 reverse: 5'-GGT-
GTCGTCCATCCTCTGTT-3'; Ddit4 forward: 5'-T-TCAT-
TCGGA-TAGCAG-3', Ddit4 reverse: 5'-TCAG GTTG
GCCAGGTG-3'; Sesn2 forward: 5'-GCATT-ACCTGCT-
GCTGCATA-3', Sesn2 reverse: 5'-AAGGCCTGGATAT-
GCTCCTT-3'; Frat2 forward: 5'-GAATCGG
GAGGGCTTCTAAC-3', Frat2 reverse: 5'-GCTCT-GCAATT-
GTA-GCACCA-3'; Cdkn1a forward: 5'-GGGATGGCAGT-
TAGGACTCA-3', Cdkn1a reverse: 5'-GTGGGGC-
AAGTGCCTAGATA-3'; 16S ribosomal protein forward: 5'-
AGATGATCGAGCCGCGC-3'; 16S ribosomal protein
reverse: 5'-GCTACCAGGGCCTTTGAGATGGA-3'
2D DIGE gel analysis
Cells were washed twice in PBS, pelleted by centrifuga-
tion, and lyzed in lysis buffer (7 M urea, 2 M thiourea, 4%
w/v CHAPS, 30 mM Tris-HCl, pH 8.5) by sonication.
Insoluble material was removed by centrifugation at
12000 g for 5 min at 4°C. Precipitation of proteins was
performed using the 2D clean-up kit (GE healthcare)
according to manufacture guidelines and protein concen-
tration was determined using the RC/DC protein assay
(Bio-Rad). 50 μg of each lysate was labeled with Cy3 and
Cy5 (400 pmol) in the dark for 30 min and quenched
with 50-fold molar excess of free lysine-to-dye. Samples
were reverse-labeled in order to enable all comparisons
and eliminate any dye-labeling bias. Additionally samples
were mixed and run on the same gels with an equal
amount (50 μg) of Cy2-labeled standard. Cy2 was used as
a standard on all gels to aid image matching and cross-gel
statistical analysis.
Isoelectric focusing (IEF) was performed with IPGphor
apparatus (GE Healthcare) according to manufacturer's
instruction. Briefly, immobilized 24 cm linear pH gradi-
ent (IPG) strips, pH 3-10, were rehydrated (30 mM Tris
Base,7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG buffer,
50 mM DTT PH 8,5) overnight. The strips were focused
according to the following protocol: linear ramp to 1000
V over 2 h, linear ramp to 4000 V over 1 h, linear ramp to
8000 V over 1 h and 8000 V for 68 kVh. Strips were equil-
ibrated for 15 min in equilibration buffer (1.5 M TrisCl,
pH 8.8, 6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS, and
trace amounts of bromphenol blue) containing 1% (w/v)
DTT and thereafter in SDS Equilibration buffer containing
4% (w/v) iodoacetamide for 15 additional min. After
equilibration, proteins were separated on 12% polyacryla-
mide gels using an Ettan Dalt Six device (GE Healthcare)
at 22°C. Gels were run at 2.5 W/gel for 30 min and then
15 W/gel until the tracking dye had migrated off the bot-
tom of the gel.
Image analysis
Gels were scanned with a Typhoon 9410 variable mode
imager (Amersham Biosciences) using excitation/emis-
sion wavelengths specific for Cy2 (488 nm/520 nm), Cy3
(532 nm/580 nm), and Cy5 (633 nm/670 nm). Images
were normalized, statistically analyzed, and differentially
expressed proteins were identified and quantified using
DeCyder (GE Healthcare). MS identification was carried
out for proteins that showed more than two-fold variation
in abundance. Briefly, the protein spots were cut out of 2-
D gels using Gelpix Spot-Excision Robot (Genetix, Hamp-
shire, UK) and then washed three times with Milli-Q
water. According to the manufacture of ZipPlate micro-
SPE Plate, gel pieces were transferred into ZipPlate micro-
SPE Plate wells (Millipore, Billerica, MA, USA). The gel
pieces were dried in a vacuum and the proteins were
digested overnight in 10 ml trypsin (10 ng/ml, Trypsin
Gold, mass spectrometry grade, Promega, Madison, WI,
USA) in 25 mM ammonium bicarbonate at 37°C. Peptide
fragments were extracted with 0.2% TFA for 30 min,
applied onto the C18 resin, and then desalted with 0.2%
TFA. The tryptic peptide mixtures were recovered with 5
ml elution solution containing 50% ACN/0.1% TFA by
centrifugation for 15 s at 17506 g and spotted onto a
MALDI sample target plate. Peptide mass spectra were
obtained on a MALDI-TOF/TOF mass spectrometer (4700
Proteomics Analyzer, Applied Biosystems, Foster City, CA,
USA).
Database search
Protein identification was processed and analyzed by
searching the Swiss-Prot and NCBI protein database using
the MASCOT search engine of Matrix Science, integrated
in the Global Protein Server (GPS) Workstation. The mass
tolerance, the most important parameter, was limited to
50 ppm. The results from the MS and MS/MS spectra were
accepted as a good identification when the GPS score con-
fidence was higher than 95%.BMC Genomics 2009, 10:408 http://www.biomedcentral.com/1471-2164/10/408
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Statistical analysis
The nuclear run-on data was statistically analyzed by
Genedata AG (Basel, Switzerland). The p-value cut-off was
set to 0.0001 or 0.001 and the expected number of tran-
scripts with p-values below these thresholds are about 15
or 150, respectively, assuming random effects only
(33155 transcripts on the microarray, thereof ~15000
with valid values). False discovery rates (FDR) were esti-
mated according to a balanced permutation test with 500
repeats. In addition the ratios of the groups means (N-fold
changes) were determined. The significant transcripts
were in addition determined on the condition that at least
2 out of 3 experiments have valid values in each group.
Representative data are shown. For the quantitative real
time verification of microarray data, gene expression was
shown as mean values ± standard deviation (SD). Means
were checked for statistical significance using 1-way anal-
ysis of variance (ANOVA), followed by Tukey tests. Differ-
ences having a P value < 0.05 were considered to be
statistically significant.
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